

=> d his

(FILE 'HOME' ENTERED AT 12:59:47 ON 05 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006

L1 STRUCTURE UPLOADED

L2 7 S L1

L3 96 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006

L4 56 S L3

L5 1 S L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)

L6 38 S L3/THU

L7 17 S L6 AND PPAR

L8 3 S L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

L9 5 S L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006

SEL L2

SEL L3

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006
SEA CIGLITAZONE AND ASTHMA

1 FILE AGRICOLA
1 FILE BIOENG
5 FILE BIOSIS
1 FILE BIOTECHABS
1 FILE BIOTECHDS
1 FILE CABA
12 FILE CAPLUS
5 FILE DDFU
5 FILE DRUGU
12 FILE EMBASE
6 FILE ESBIODBASE
4 FILE IFIPAT
1 FILE LIFESCI
7 FILE MEDLINE
4 FILE PASCAL
9 FILE SCISEARCH
1 FILE TOXCENTER
390 FILE USPATFULL
62 FILE USPAT2
5 FILE WPIDS
1 FILE WPIFV
5 FILE WPINDEX
24 FILE EPFULL
101 FILE IMSPATENTS
1 FILE INPADOC
1 FILE PATDPAFULL
259 FILE PCTFULL

L10 QUE CIGLITAZONE AND ASTHMA

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006

L11 649 S CIGLITAZONE AND ASTHMA

L12 203 S L11 AND PPAR

FILE 'EMBASE, CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006

L13 24 S CIGLITAZONE AND ASTHMA

L14 18 S L13 AND PPAR

L15 14 DUP REM L14 (4 DUPLICATES REMOVED)
L16 0 S L14 NOT PY>2002

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
L17 18 S L12 NOT PY>2002

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006
SEA (E9-E111) AND ASTHMA

1 FILE CAPLUS
1 FILE IFIPAT
21 FILE USPATFULL
2 FILE USPAT2
1 FILE WPIDS
1 FILE WPINDEX
22 FILE PCTFULL

L18 QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006
L19 43 S (E9-E111) AND ASTHMA
L20 14 S L19 NOT PY>2003

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2006 HIGHEST RN 905816-92-4
DICTIONARY FILE UPDATES: 4 SEP 2006 HIGHEST RN 905816-92-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10674395.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:00:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 57 TO ITERATE

100.0% PROCESSED 57 ITERATIONS
SEARCH TIME: 00.00.01


7 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 688 TO 1592
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d 12 scan


L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[2-(2-benzofuranyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C24 H20 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[2-[(3,5-dimethoxyphenoxy)methyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C25 H26 N2 O7 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-(2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]- (9CI)
MF C21 H18 N2 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4-Thiazolidinedione, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-5-(2-naphthalenylsulfonyl)- (9CI)
 MF C32 H26 N2 O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4-Thiazolidinedione, 5-[[4-[2-[5-methyl-2-[1-(2-pyridinylthio)ethyl]-4-oxazolyl]ethoxy]phenyl]methyl]-5-(2-naphthalenylsulfonyl)- (9CI)
 MF C23 H23 N3 O4 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4-Thiazolidinedione, 5-[[4-[2-[5-methyl-2-(1-methyl-3-cyclohexen-1-yl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
 MF C23 H26 N2 O4 S
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
 IN 2,4-Thiazolidinedione, 5-[[4-[(2-phenyl-4-thiazolyl)methoxy]phenyl]methyl]- (9CI)
 MF C20 H16 N2 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
 FULL SEARCH INITIATED 13:03:15 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 1125 TO ITERATE

100.0% PROCESSED 1125 ITERATIONS
 SEARCH TIME: 00.00.01

96 ANSWERS

L3 96 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
169.14	169.35

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2006 VOL 145 ISS 11
FILE LAST UPDATED: 4 Sep 2006 (20060904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 56 L3

=> s l4 and (asthma or allergy or hypersensitivity)

32098 ASTHMA
44344 ALLERGY
20887 HYPERSENSITIVITY

L5 1 L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)

=> d l5 1 ti

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI peroxisome proliferator-activated receptor- α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

=> d l4 1-6 ti

L4 ANSWER 1 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

L4 ANSWER 2 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Molecular docking studies on pyridine derivatives of glitazones as PPAR γ agonists

L4 ANSWER 3 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

L4 ANSWER 4 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Therapeutic uses of dunaliella powder

L4 ANSWER 5 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of 2-(5-phosphono)furanyl substituted heteroaromatic compounds as fructose-1,6-bisphosphatase (FBPase) inhibitors for use in combination with insulin sensitizers for the treatment of diabetes

L4 ANSWER 6 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones

=> s 13/thu

56 L3
 807585 THU/RL
 L6 38 L3/THU
 (L3 (L) THU/RL)

=> s 16 and PPAR

7940 PPAR
 L7 17 L6 AND PPAR

=> s 17 and (asthma or allergy or inflammation)

32098 ASTHMA
 44344 ALLERGY
 157219 INFLAMMATION
 L8 3 L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

=> d 18 1-3 ti

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI peroxisome proliferator-activated receptor- α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF- α responses of macrophages to lipopolysaccharide in vitro or in vivo

=> d 18 1-3 ti abs bib

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

AB In one aspect, the present invention provides methods for determining whether an agent (e.g., candidate drug) possesses a biol. activity and populations of nucleic acid mols. useful as probes for measuring the level of expression of populations of genes. The methods comprise includes 3 steps. Efficacy values of the agents are compared to at least one reference efficacy value to thield an efficacy comparison result, wherein each efficacy value represents at least one expression pattern of the same efficacy-related population of genes, or at least one expression pattern of the same efficacy-related population of proteins. Toxicity values of the agent are compared to at least one reference toxicity value to yield a toxicity

comparison result based on gene expression in an analogous fashion. Third, a classifier value of the agent is compared to at least one reference classifier value to yield a classifier comparison value. The comparison result(s) obtained from efficacy, toxicity, and classifier values determine whether the agent possesses the defined biol. activity. The method is exemplified by identified gene expression patterns for agonists, or partial agonists, of peroxisome proliferator-activator receptor γ (PPAR γ) in mouse and rat models.

AN 2005:348905 CAPLUS

DN 142:385959

TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

IN Lum, Pek Yee; Tan, Yejun; Dai, Hongyue; Muise, Eric Stanley; Berger, Joel P.; Thompson, John R.

PA USA

SO U.S. Pat. Appl. Publ., 51 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005084872	A1	20050421	US 2004-764420	20040123
PRAI	US 2003-442797P	P	20030124		
	US 2003-474413P	P	20030530		

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI peroxisome proliferator-activated receptor- α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of a cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor- α agonist and a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation described), or prodrug thereof. Compns., pharmaceutical compns., and kits for effecting the particular methods are also described.

AN 2003:570750 CAPLUS

DN 139:111706

TI peroxisome proliferator-activated receptor- α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

IN Needleman, Philip

PA Pharmacia Corporation, USA

SO PCT Int. Appl., 157 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003059271	A2	20030724	WO 2003-US1099	20030114
	WO 2003059271	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,	
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
US	2003220374	A1 20031127 US 2003-341174 20030113
CA	2472199	AA 20030724 CA 2003-2472199 20030114
AU	2003207557	A1 20030730 AU 2003-207557 20030114
AU	2003207557	A2 20030730
EP	1465621	A2 20041013 EP 2003-705768 20030114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
CN	1642544	A 20050720 CN 2003-805886 20030114
BR	2003006872	A 20050906 BR 2003-6872 20030114
JP	2006501136	T2 20060112 JP 2003-559436 20030114
ZA	2004005562	A 20051004 ZA 2004-5562 20040713
PRAI	US 2002-348298P	P 20020114
	US 2003-341174	A 20030113
	WO 2003-US1099	W 20030114
OS	MARPAT 139:111706	

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF- α responses of macrophages to lipopolysaccharide in vitro or in vivo

AB The authors investigated the potential use of peroxisome proliferator-activated receptor γ (PPAR γ) agonists as anti-inflammatory agents in cell-based assays and in a mouse model of endotoxemia. Human peripheral blood monocytes were treated with LPS or PMA and a variety of PPAR γ agonists. Although 15-deoxy- Δ 12,14-prostaglandin J2 (15d-PGJ2) at micromolar concns. inhibited the production of TNF- α and IL-6, 4 other high affinity PPAR γ ligands failed to affect cytokine production. Similar results were obtained when the monocytes were allowed to differentiate in culture into macrophages that expressed higher levels of PPAR γ or when the murine macrophage cell line RAW 264.7 was used. Furthermore, saturating concns. of a potent PPAR γ ligand not only failed to block cytokine production, but also were unable to block the inhibitory activity of 15d-PGJ2. Thus, activation of PPAR γ does not appear to inhibit the production of cytokines by either monocytes or macrophages, and the inhibitory effect observed with 15d-PGJ2 is most likely mediated by a PPAR γ -independent mechanism. To examine the anti-inflammatory activity of PPAR γ agonists in vivo, db/db mice were treated with a potent thiazolidinedione that lowered their elevated blood glucose and triglyceride levels as expected. When thiazolidinedione-treated mice were challenged with LPS, they displayed no suppression of cytokine production. Rather, their blood levels of TNF- α and IL-6 were elevated beyond the levels observed in control db/db mice challenged with LPS. Comparable results were obtained with the corresponding lean mice. Thus, compds. capable of activating PPAR γ in leukocytes will not be useful for the treatment of acute inflammation.

AN 2000:52487 CAPLUS

DN 132:202817

TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF- α responses of macrophages to lipopolysaccharide in vitro or in vivo

AU Thieringer, Rolf; Fenyk-Melody, Judy E.; Le Grand, Cheryl B.; Shelton, Beverly A.; Detmers, Patricia A.; Somers, Elizabeth P.; Carbin, Linda; Moller, David E.; Wright, Samuel D.; Berger, Joel

CS Departments of Endocrinology and Chemical Biology, Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Journal of Immunology (2000), 164(2), 1046-1054
CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 16 and (asthma or allergy or inflammation)

32098 ASTHMA

44344 ALLERGY

157219 INFLAMMATION

L9 5 L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

=> d 19 1-5 ti

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Methods and compositions for treating glucose-associated conditions,
metabolic syndrome, dyslipidemias and other conditions

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Gene expression profiles for determining whether an agent possesses a
defined biological activity using efficacy, toxicity, and classifier
comparisons

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Combination treatment for diabetes and related diseases using exendins and
thiazolidinediones

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI peroxisome proliferator-activated receptor- α agonist- and
cyclooxygenase-2 selective inhibitor-containing compositions, and methods
of treatment using them

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Activation of peroxisome proliferator-activated receptor γ does not
inhibit IL-6 or TNF- α responses of macrophages to lipopolysaccharide
in vitro or in vivo

=> d 19 1 3 ti abs bib

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Methods and compositions for treating glucose-associated conditions,
metabolic syndrome, dyslipidemias and other conditions

AB The invention relates, in part, to of glutamic acid boroproline
(Glu-boroPro) containing compds. and methods of use thereof in the prevention
or management of conditions that are associated with impaired glucose
tolerance such as diabetes. The invention also relates to compns. of
Glu-boroPro containing compds. and methods of use thereof in the prevention or
management of conditions such as metabolic syndrome, dyslipidemias,
inflammation, cardiovascular disorders such as hypertension and
atherosclerosis, and to reduce body weight or prevent weight gain. The compds.
of the invention are also useful in lowering levels of triglycerides, free
fatty acids, C-reactive protein (CRP), HbA1C, total glycosylated Hb
(TGHb), in increasing insulin sensitivity index and in stimulating insulin
release. The method may further comprise administering a second agent
such as an antidiabetic agent. The inhibition of the serine protease
DPP-IV by the compds. in vitro and vivo was determined

AN 2006:295558 CAPLUS

DN 144:343604

TI Methods and compositions for treating glucose-associated conditions,
metabolic syndrome, dyslipidemias and other conditions

IN Aziz, Nazneen; Jesson, Michael I.; McLean, Paul, A.; Miller, Glenn T.;
Jones, Barry

PA Point Therapeutics, Inc., USA

SO PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034435	A2	20060330	WO 2005-US34112	20050921
	WO 2006034435	A3	20060803		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006094693	A1	20060504	US 2005-233532	20050921
PRAI	US 2004-612069P	P	20040921		
	US 2004-622466P	P	20041027		
	US 2005-700871P	P	20050719		
	US 2005-704157P	P	20050729		
OS	MARPAT 144:343604				

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones
AB The invention provides methods for treatment and/or prevention of diabetes and diabetes-related diseases. More specifically, the methods and uses of the invention pertains to administration of an exendin-4 compound in combination with administration of a thiazolidinedione insulin sensitizer.
AN 2004:490736 CAPLUS
DN 141:47336
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones
IN Knudsen, Lotte Bjerre
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050115	A2	20040617	WO 2003-DK824	20031201
	WO 2004050115	A3	20040722		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003283216	A1	20040623	AU 2003-283216	20031201
	EP 1569682	A2	20050907	EP 2003-775117	20031201
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	EP 1688148	A1	20060809	EP 2006-112986	20031201
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK		
US 2004180824	A1	20040916	US 2003-726734 20031203
US 2006189535	A1	20060824	US 2006-414114 20060428
PRAI DK 2002-1864	A	20021203	
US 2002-431999P	P	20021209	
EP 2003-775117	A3	20031201	
WO 2003-DK824	W	20031201	
US 2003-726734	B1	20031203	

=> sel 12

NO ANSWERS SELECTED. THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
An answer set can be processed to create terms only
in the same file in which it was created.

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.78	213.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2006 HIGHEST RN 905816-92-4
DICTIONARY FILE UPDATES: 4 SEP 2006 HIGHEST RN 905816-92-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> sel 12

E1 THROUGH E8 ASSIGNED

=> sel 13

E9 THROUGH E111 ASSIGNED

=> index bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.43	247.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

```
=> s ciglitazone and asthma
      1  FILE AGRICOLA
      1  FILE BIOENG
      5  FILE BIOSIS
      1  FILE BIOTECHABS
      1  FILE BIOTECHDS
      1  FILE CABA
     12  FILE CAPLUS
      5  FILE DDFU
      5  FILE DRUGU
     12  FILE EMBASE
      6  FILE ESBIODASE
      4  FILE IFIPAT
      1  FILE LIFESCI
      7  FILE MEDLINE
```

45 FILES SEARCHED...

```
      4  FILE PASCAL
      9  FILE SCISEARCH
      1  FILE TOXCENTER
    390  FILE USPATFULL
     62  FILE USPAT2
      5  FILE WPIDS
      1  FILE WPIFV
      5  FILE WPINDEX
     24  FILE EPFULL
    101  FILE IMSPATENTS
      1  FILE INPADOC
```

78 FILES SEARCHED...

```
      1  FILE PATDPAFULL
    259  FILE PCTFULL
```

27 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L10 QUE CIGLITAZONE AND ASTHMA

```
=> file uspatfull pctfull
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.83	249.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'USPATFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
COPYRIGHT (C) 2006 Univentio

```
=> s ciglitazone and asthma
```

L11 649 CIGLITAZONE AND ASTHMA

=> s l11 and PPAR

L12 203 L11 AND PPAR

=> d l12 1-10 ti

'1-10' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ti

L12 ANSWER 1 OF 203 USPATFULL on STN

TI Thiazole and thiadiazole inhibitors of tyrosine phosphatases

=> d l12 1-10 ti

L12 ANSWER 1 OF 203 USPATFULL on STN

TI Thiazole and thiadiazole inhibitors of tyrosine phosphatases

L12 ANSWER 2 OF 203 USPATFULL on STN

TI Albumin fusion proteins

L12 ANSWER 3 OF 203 USPATFULL on STN

TI Protein HDPBQ71

L12 ANSWER 4 OF 203 USPATFULL on STN

TI Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents

L12 ANSWER 5 OF 203 USPATFULL on STN

TI Novel piperazines

L12 ANSWER 6 OF 203 USPATFULL on STN

TI Modulators of FAAH

L12 ANSWER 7 OF 203 USPATFULL on STN

TI Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene

L12 ANSWER 8 OF 203 USPATFULL on STN

TI Methods of treating and diagnosing diabetes with cx3cr1 modulators

L12 ANSWER 9 OF 203 USPATFULL on STN

TI Novel therapeutic method and compositions for topical administration

L12 ANSWER 10 OF 203 USPATFULL on STN

TI Novel therapeutic method and compositions for topical administration

=> file embase caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.94

252.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.75

FILE 'EMBASE' ENTERED AT 13:11:28 ON 05 SEP 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ciglitazone and asthma
L13 24 CIGLITAZONE AND ASTHMA

=> s l13 and ppar
L14 18 L13 AND PPAR

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15 14 DUP REM L14 (4 DUPLICATES REMOVED)

=> s l14 not py>2002
L16 0 L14 NOT PY>2002

=> file uspatfull pctfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.69	262.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'USPATFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
COPYRIGHT (C) 2006 Univentio

=> s l12 not py>2002
L17 18 L12 NOT PY>2002

=> d l17 1-18 ti

L17 ANSWER 1 OF 18 USPATFULL on STN
TI Substituted imidazoles, their preparation and use

L17 ANSWER 2 OF 18 USPATFULL on STN
TI Modulators of protein tyrosine phosphatases (PTPases)

L17 ANSWER 3 OF 18 USPATFULL on STN
TI Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

L17 ANSWER 4 OF 18 USPATFULL on STN
TI Imidazole compounds

L17 ANSWER 5 OF 18 USPATFULL on STN
TI Pharmaceutical compositions of glycogen phosphorylase inhibitors

L17 ANSWER 6 OF 18 USPATFULL on STN
TI Compositions and methods for the treatment of Alzheimer's disease,
central nervous system injury, and inflammatory diseases

L17 ANSWER 7 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED
USES
TIFR COMPOSES D'ETHER ET COMPOSITIONS POUR LA GESTION DU CHOLESTEROL ET
UTILISATIONS ASSOCIEES

L17 ANSWER 8 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
 TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES

L17 ANSWER 9 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
 TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3

L17 ANSWER 10 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
 TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE

L17 ANSWER 11 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L17 ANSWER 12 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L17 ANSWER 13 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
 TIFR MODULATEURS DE PROTEINES TYROSINE PHOSPHATAGES (PTPases)

L17 ANSWER 14 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
 TIFR MODULATEURS DE PROTEINE TYROSINE PHOSPHATASE (PTPases)

L17 ANSWER 15 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN PIPERIDYL-IMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THERAPEUTIC USES
 TIFR DERIVES DE PIPERIDYLE-IMIDAZOLE, PREPARATIONS DANS LESQUELLES ILS
 ENTRENT ET UTILISATIONS THERAPEUTIQUES DE CES DERNIERES

L17 ANSWER 16 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
 TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION

L17 ANSWER 17 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
 TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION

L17 ANSWER 18 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
 CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
 TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
 LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES

=> d 117 1 2 4 6 8 9 10 16 17 18 ti abs bib

L17 ANSWER 1 OF 18 USPATFULL on STN
 TI Substituted imidazoles, their preparation and use
 AB A class of substituted imidazole compounds of formula I ##STR1##

methods for their preparation, pharmaceutical compositions comprising
 them and use thereof in the treatment of disorders related to the
 histamine H3 receptor are disclosed. More particularly, these compounds
 possess histamine H3 receptor antagonistic activity and are thus useful
 for the treatment of disorders in which a histamine H3 receptor blockade
 is beneficial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:168250 USPATFULL
 TI Substituted imidazoles, their preparation and use
 IN Dorwald, Florencio Zaragoza, Ballerup, DENMARK

Andersen, Knud Erik, Br.o slashed.ndby, DENMARK
PA Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GERMANY,
FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6417218 B1 20020709
AI US 2000-484621 20000118 (9)
PRAI DK 1999-54 19990118
US 1999-116510P 19990120 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Green, Esq., Reza, Waibel, Esq., Peter J.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 18 USPATFULL on STN

TI Modulators of protein tyrosine phosphatases (PTPases).
AB Disclosed are novel compounds, novel compositions, methods of their use,
and methods of their manufacture, where such compounds of Formula 1 are
pharmacologically useful inhibitors of Protein Tyrosine Phosphatases
(PTPase's) including PTP1B, T cell PTP, ##STR1##

wherein n, m, X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6,
and R.sub.7 are defined more fully in the description. The compounds are
useful in the treatment of type I diabetes, type II diabetes, impaired
glucose tolerance, insulin resistance, obesity, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:152652 USPATFULL
TI Modulators of protein tyrosine phosphatases (PTPases)
IN Andersen, Henrik Sune, Lyngby, DENMARK
Hansen, Thomas Kruse, Herlev, DENMARK
Lau, Jesper, Farum, DENMARK
M.o slashed.ller, Niels Peter Hundahl, K.o slashed.benhavn .O slashed.,
DENMARK
Olsen, Ole Hvilsted, Br.o slashed.nsh.o slashed.j, DENMARK
Axe, Frank Urban, Escondido, CA, United States
Ge, Yu, San Diego, CA, United States
Holsworth, Daniel Dale, San Diego, CA, United States
Jones, Todd Kevin, Solana Beach, CA, United States
Judge, Luke Milburn, Seattle, WA, United States
Ripka, William Charles, San Diego, CA, United States
Shapira, Barry Zvi, Acton, CA, United States
Uyeda, Roy Teruyuki, San Diego, CA, United States
PA Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)
Ontogen Corporation, Carlsbad, CA, United States (U.S. corporation)
PI US 6410556 B1 20020625
AI US 2000-659547 20000911 (9)
PRAI DK 1999-1277 19990910
DK 2000-1069 20000707
US 1999-156742P 19990930 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Green, Esq., Reza, Waibel, Esq., Peter J.
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 18 USPATFULL on STN

TI Imidazole compounds

AB A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:112918 USPATFULL

TI Imidazole compounds

IN Andersen, Knud Erik, Brondby, DENMARK

Dorwald, Florencio Zaragiza, Ballerup, DENMARK

Peschke, Bernd, Malov, DENMARK

Sidelmann, Ulla Grove, Valby, DENMARK

Rudolf, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF

Stenkamp, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF

Hurnaus, Rudolf, Biberach, GERMANY, FEDERAL REPUBLIC OF

Muller, Stephan Georg, Warthausen, GERMANY, FEDERAL REPUBLIC OF

Krist, Bernd, Ulm, GERMANY, FEDERAL REPUBLIC OF

Eriksen, Birgitte, Farum, GERMANY, FEDERAL REPUBLIC OF

PI US 2002058659 A1 20020516

US 6437147 B2 20020820

AI US 2001-810237 A1 20010316 (9)

PRAI DK 2000-441 20000317

DK 2000-1016 20000629

US 2000-193741P 20000331 (60)

US 2000-216553P 20000707 (60)

DT Utility

FS APPLICATION

LREP Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400,
405 Lexington Avenue, New York, NY, 10174-6401

CLMN Number of Claims: 42

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 18 USPATFULL on STN

TI Compositions and methods for the treatment of Alzheimer's disease,
central nervous system injury, and inflammatory diseases

AB The present invention relates to methods and compositions for treating
Alzheimer's disease and other diseases and conditions with an
inflammatory component (e.g., central nervous system injury). In
particular, the present invention provides agents that regulate the
production of proinflammatory and neurotoxic products involved in
Alzheimer's disease and other diseases and conditions with an
inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:25919 USPATFULL

TI Compositions and methods for the treatment of Alzheimer's disease,
central nervous system injury, and inflammatory diseases

IN Landreth, Gary, Shaker Heights, OH, United States

Combs, Colin, University Heights, OH, United States

Silver, Jerry, Bay Village, OH, United States

Fitch, Michael T., S. Euclid, OH, United States

PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)

PI US 6191154 B1 20010220

AI US 1998-200700 19981127 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Criares, Theodore J.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
ABEN The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatological, cardiovascular immunological, neurological, ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, and a PPAR γ ; agonist which cross-activates PPAR α ; or PPAR δ ; or both, or a PPAR γ ; partial agonist, or a PPAR γ /RXR agonist, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.
ABFR L'invention concerne des procedes d'utilisation de ligands PPAR dans le traitement de maladies inflammatoires endocrines, dermatologiques, cardio-vasculaires, immunologiques, neurologiques, ophtalmiques, neoplasiques, pulmonaires, et de dysfonctionnements lies a l'age. L'invention concerne de plus des methodes de traitement de ces etats et maladies, qui comprennent l'etape consistant a administrer a un etre humain ou a un animal necessitant un tel traitement une quantite therapeutique de compositions pharmacologiques contenant un excipient pharmaceutiquement acceptable et un agoniste de PPAR γ ; qui active par reaction croisee PPAR α ; et/ou PPAR δ ; ou un agoniste partiel de PPAR γ ; ou un agoniste de PPAR γ /RXR permettant d'inverser, de ralentir, d'arreter ou de prevenir le processus inflammatoire ou degeneratif.
AN 2002013812 PCTFULL ED 20020711 EW 200208
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
IN PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
PA PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
LAF English
LA English
DT Patent
PI WO 2002013812 A1 20020221
DS W: AU CA MX NZ US
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
AI WO 2001-US25668 A 20010816
PRAI US 2000-60/225,907 20000817
US 2000-60/230,509 20000906

L17 ANSWER 9 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3
ABEN A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
ABFR L'invention concerne une nouvelle classe de composes heterocycliques d'imidazo, des compositions pharmaceutiques renfermant ces composes et

leur utilisation dans le traitement et/ou la prevention de maladies et troubles lies au recepteur d'histamine H3. Plus specifiquement, les composes sont utilises pour le traitement et/ou la prevention de maladies et troubles, dans lesquels une interaction avec le recepteur d'histamine H3 s'avere benefique.

AN 2001068652 PCTFULL ED 20020822
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3
IN ANDERSEN, Knud, Erik;
DOERWALD, Florencio, Zaragoza;
SIDELMANN, Ulla, Grove;
RUDOLF, Klaus;
STENKAMP, Dirk;
HURNAUS, Rudolf;
MUELLER, Stephan, Georg;
KRIST, Bernd;
ERIKSEN, Birgitte;
PESCHE, Bernd

PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL GMBH

DT Patent

PI WO 2001068652 A1 20010920

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
NE SN TD TG

AI WO 2001-DK188 A 20010316

PRAI DK 2000-PA 2000 00441 20000317

DK 2000-PA 2000 01016 20000629

L17 ANSWER 10 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS

TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE

ABEN A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

ABFR L'invention concerne une classe de composes heterocycliques imidazo, des compositions pharmaceutiques les comprenant et leur utilisation dans le traitement et/ou la prevention de maladies et de troubles associes au recepteur H3 de l'histamine. En particulier, ces composes sont utiles pour le traitement et/ou la prevention de maladies et de troubles dans lesquels une interaction avec le recepteur H3 de l'histamine est benefique.

AN 2001068651 PCTFULL ED 20020822

TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS

TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE

IN ANDERSEN, Knud, Erik;
DOERWALD, Florencio, Zaragoza;
PESCHKE, Bernd

PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL GMBH

DT Patent

PI WO 2001068651 A1 20010920

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA

UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
 AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
 IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
 NE SN TD TG

AI WO 2001-DK187 A 20010316
 PRAI DK 2000-PA 2000 00442 20000317

L17 ANSWER 16 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
 TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
 ABEN A novel class of substituted imidazole compounds (I), pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is beneficial.

ABFR L'invention concerne une nouvelle classe de composees imidazoles substitues (I), des compositions pharmaceutiques contenant ces composees, ainsi que l'utilisation de ceux-ci dans le traitement et/ou la prevention de maladies et troubles associes au recepteur H3 de l'histamine. Ces composees sont notamment utiles dans le traitement et/ou la prevention de maladies et troubles, dans lesquels une interaction avec le recepteur H3 de l'histamine est benefique.

AN 2000063208 PCTFULL ED 20020515
 TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
 TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
 IN DoerWALD, Florencio, Zaragoza;
 ANDERSEN, Knud, Erik;
 JORGENSEN, Tine, Krogh;
 PESCHKE, Bernd;
 WULFF, Birgitte, Schjellerup;
 PETTERSSON, Ingrid;
 RUDOLF, Klaus;
 STENKAMP, Dirk;
 HURNAUS, Rudolf;
 MUELLER, Stephan, Georg;
 KRIST, Bernd

PA NOVO NORDISK A/S;
 BOEHRINGER INGELHEIM INTERNATIONAL, GMBH

LA English
 DT Patent

PI WO 2000063208 A1 20001026

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO
 NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ
 VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG
 KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
 MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AI WO 2000-DK179 A 20000413
 PRAI DK 1999-PA 1999 00508 19990416
 DK 1999-PA 1999 01345 19990922
 DK 2000-PA 2000 00042 20000112

L17 ANSWER 17 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
 TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
 ABEN A novel class of substituted imidazole derivatives, methods for their

preparation,
pharmaceutical compositions comprising them and use thereof in the
treatment of disorders related to
the histamine H3 receptor. More particularly, the compounds possess
histamine H3 receptor
antagonistic activity and are thus useful for the treatment of disorders
in which a histamine H3
receptor blockade is beneficial. The compounds have general formula (I).
ABFR L'invention concerne une nouvelle classe de derives d'imidazole
substitues, leurs procedes de
preparation, des compositions pharmaceutiques les renfermant et leur
utilisation dans le traitement
de troubles se rapportant au recepteur H3 de l'histamine. Plus
precisement, les composees, qui
presentent une activite antagoniste du recepteur H3 de l'histamine, sont
par consequent utiles au
traitement de troubles dans lesquels un blocage du recepteur H3 de
l'histamine est benefique. Les
composees presentent la formule generale (I).
AN 2000042023 PCTFULL ED 20020515
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
IN ANDERSEN, Knud, Erik;
DoerWALD, Florencio, Zaragoza
PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL, GMBH;
ANDERSEN, Knud, Erik;
DoerWALD, Florencio, Zaragoza
LA English
DT Patent
PI WO 2000042023 A1 20000720
DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 2000-DK10 A 20000112
PRAI DK 1999-PA 1999 00054 19990118
US 1999-60/116,510 19990120
L17 ANSWER 18 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
ABEN The present invention relates to methods and compositions for treating
Alzheimer's disease and
other diseases and conditions with an inflammatory component (e.g.,
central nervous system injury).
In particular, the present invention provides agents that regulate the
production of proinflammatory
and neurotoxic products involved in Alzheimer's disease and other
diseases and conditions with an
inflammatory component.
ABFR La presente invention concerne des methodes et des compositions de
traitement de la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante
inflammatoire (par exemple, des
lesions au systeme nerveux central). En particulier, la presente
invention concerne des agents
regulant la production de produits pro-inflammatoires et neurotoxiques
appliquees dans la maladie

d'Alzheimer ainsi que d'autres maladies et etats a composante inflammatoire.

AN 2000032190 PCTFULL ED 20020515
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
IN LANDRETH, Gary;
COMBS, Colin;
SILVER, Jerry;
FITCH, Michael, T.
PA CASE WESTERN RESERVE UNIVERSITY
LA English
DT Patent
PI WO 2000032190 A1 20000608
DS W: AU CA IL JP KR AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE
AI WO 1999-US27987 A 19991124
PRAI US 1998-09/200,700 19981127

=> index bioscience patents

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPAT2' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
20.49	282.51

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.75

CA SUBSCRIBER PRICE

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E9-E111) and asthma

1 FILE CAPLUS
16 FILES SEARCHED...
29 FILES SEARCHED...
1 FILE IFIPAT
38 FILES SEARCHED...
51 FILES SEARCHED...
21 FILE USPATFULL
2 FILE USPAT2
1 FILE WPIDS
66 FILES SEARCHED...
1 FILE WPINDEX
68 FILES SEARCHED...
78 FILES SEARCHED...
86 FILES SEARCHED...
22 FILE PCTFULL

7 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L18 QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"/BI OR "BM
131246"/BI OR "TZD 2"/BI OR "TZD 300512"/BI OR 103787-85-5/BI OR 10378
7-86-6/BI OR 103787-87-7/BI OR 103787-88-8/BI OR 103787-89-9/BI OR 103

787-90-2/BI OR 103787-91-3/BI OR 103787-92-4/BI OR 103787-93-5/BI OR 1
 03787-94-6/BI OR 103787-95-7/BI OR 103787-96-8/BI OR 103787-97-9/BI OR
 103787-98-0/BI OR 103787-99-1/BI OR 103788-00-7/BI OR 103788-01-8/BI
 OR 103788-02-9/BI OR 103788-03-0/BI OR 103788-04-1/BI OR 103788-05-2/B
 I OR 103788-06-3/BI OR 103788-07-4/BI OR 103788-08-5/BI OR 103788-09-6
 /BI OR 103788-10-9/BI OR 103788-11-0/BI OR 103788-12-1/BI OR 103788-13
 -2/BI OR 103788-14-3/BI OR 103788-15-4/BI OR 103788-16-5/BI OR 103788-
 17-6/BI OR 103788-18-7/BI OR 103788-19-8/BI OR 103788-20-1/BI OR 10378
 8-21-2/BI OR 103788-22-3/BI OR 103788-23-4/BI OR 103788-24-5/BI OR 103
 788-25-6/BI OR 103788-26-7/BI OR 103788-27-8/BI OR 103788-28-9/BI OR 1
 03788-29-0/BI OR 103788-30-3/BI OR 103788-31-4/BI OR 103788-32-5/BI OR
 103788-33-6/BI OR 103788-34-7/BI OR 103788-58-5/BI OR 103814-32-0/BI
 OR 103814-33-1/BI OR 103926-56-3/BI OR 141399-27-1/BI OR 141399-28-2/B
 I OR 141399-29-3/BI OR 155721-78-1/BI OR 155721-79-2/BI OR 155721-80-5
 /BI OR 155721-81-6/BI OR 155721-82-7/BI OR 155721-83-8/BI OR 155721-84
 -9/BI OR 155721-85-0/BI OR 155721-86-1/BI OR 155721-87-2/BI OR 155721-
 88-3/BI OR 155721-89-4/BI OR 155721-90-7/BI OR 155721-91-8/BI OR 15572
 1-92-9/BI OR 155721-93-0/BI OR 155721-94-1/BI OR 155721-95-2/BI OR 155
 721-96-3/BI OR 155721-97-4/BI OR 155721-98-5/BI OR 155721-99-6/BI OR 1
 55722-00-2/BI OR 155722-01-3/BI OR 171269-88-8/BI OR 171269-89-9/BI OR
 171269-90-2/BI OR 171269-91-3/BI OR 171269-92-4/BI OR 171269-93-5/BI
 OR 171269-94-6/BI OR 171269-95-7/BI OR 171269-96-8/BI OR 171270-11-4/B
 I OR 171270-12-5/BI OR 186894-41-7/BI OR 500718-69-4/BI OR 500718-73-0
 /BI OR 746578-79-0/BI)) AND ASTHMA

=> file uspatfull pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.27

286.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.75

FILE 'USPATFULL' ENTERED AT 13:18:11 ON 05 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006

COPYRIGHT (C) 2006 Univentio

=> s (E9-E111) and asthma

L19

43 (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"/BI
 OR "BM 131246"/BI OR "TZD 2"/BI OR "TZD 300512"/BI OR 103787-85-
 5/BI OR 103787-86-6/BI OR 103787-87-7/BI OR 103787-88-8/BI OR
 103787-89-9/BI OR 103787-90-2/BI OR 103787-91-3/BI OR 103787-92-4
 /BI OR 103787-93-5/BI OR 103787-94-6/BI OR 103787-95-7/BI OR
 103787-96-8/BI OR 103787-97-9/BI OR 103787-98-0/BI OR 103787-99-1
 /BI OR 103788-00-7/BI OR 103788-01-8/BI OR 103788-02-9/BI OR
 103788-03-0/BI OR 103788-04-1/BI OR 103788-05-2/BI OR 103788-06-3
 /BI OR 103788-07-4/BI OR 103788-08-5/BI OR 103788-09-6/BI OR
 103788-10-9/BI OR 103788-11-0/BI OR 103788-12-1/BI OR 103788-13-2
 /BI OR 103788-14-3/BI OR 103788-15-4/BI OR 103788-16-5/BI OR
 103788-17-6/BI OR 103788-18-7/BI OR 103788-19-8/BI OR 103788-20-1
 /BI OR 103788-21-2/BI OR 103788-22-3/BI OR 103788-23-4/BI OR
 103788-24-5/BI OR 103788-25-6/BI OR 103788-26-7/BI OR 103788-27-8
 /BI OR 103788-28-9/BI OR 103788-29-0/BI OR 103788-30-3/BI OR
 103788-31-4/BI OR 103788-32-5/BI OR 103788-3

=> s l43 not py>2003

L43 NOT FOUND

The L-number entered could not be found. To see the definition
 of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l19 not py>2003

L20 14 L19 NOT PY>2003

=> d l20 1-14 ti

L20 ANSWER 1 OF 14 USPATFULL on STN

TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses

L20 ANSWER 2 OF 14 USPATFULL on STN

TI Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses

L20 ANSWER 3 OF 14 USPATFULL on STN

TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

L20 ANSWER 4 OF 14 USPATFULL on STN

TI Methods for identifying novel multimeric agents that modulate receptors

L20 ANSWER 5 OF 14 USPATFULL on STN

TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

L20 ANSWER 6 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 7 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR MIMIQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 8 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS

TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS SELECTIFS DE LA CYCLOOXYGENASE 2.

L20 ANSWER 9 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS

TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP

L20 ANSWER 10 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR

TIFR CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISES POUR PPAR

L20 ANSWER 11 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR COMPOSES D'ETHER ET COMPOSITIONS POUR LA GESTION DU CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 12 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES

L20 ANSWER 13 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES

L20 ANSWER 14 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS
TIFR TECHNIQUE D'IDENTIFICATION DE NOUVEAUX AGENTS MULTIMERES MODULANT DES
RECEPTEURS

=> d 120 1 2 3 5 6 7 8 9 10 12 13 ti abs bib

L20 ANSWER 1 OF 14 USPATFULL on STN
TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid
derivatives, compositions thereof, and methods of cholesterol management
and related uses
AB The invention relates to novel Acyl coenzyme-A mimics, compositions
comprising ketone compounds, and methods useful for treating and
preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and
glucose metabolism disorders comprising administering a composition
comprising a ketone compound. The Acyl coenzyme-A mimics, compositions,
and methods of the invention are also useful for treating and preventing
Alzheimer's Disease, Syndrome X, peroxisome proliferator activated
receptor-related disorders, septicemia, thrombotic disorders, obesity,
pancreatitis, hypertension, renal disease, cancer, inflammation,
bacterial infection and impotence. In certain embodiments, the Acyl
coenzyme-A mimics, compositions, and methods of the invention are useful
in combination therapy with other therapeutics, such as
hypocholesterolemic and hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:335335 USPATFULL
TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid
derivatives, compositions thereof, and methods of cholesterol management
and related uses
IN Dasseux, Jean-Louis, Ann Arbor, MI, UNITED STATES
Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
PI US 2003236213 A1 20031225
AI US 2003-410444 A1 20030410 (10)
PRAI US 2002-371511P 20020410 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC,
20006
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 14 USPATFULL on STN
TI Functionalized long chain derivatives as acyl coenzyme-A mimics,
compositions thereof, and methods of cholesterol management and related
uses
AB The invention relates to novel Acyl coenzyme-A mimics, compositions
comprising ketone compounds, and methods useful for treating and
preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and
glucose metabolism disorders comprising administering a composition

comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:335334 USPATFULL
TI Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
IN Dasseux, Jean-Louis, Ann Arbor, MI, UNITED STATES
Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
PI US 2003236212 A1 20031225
AI US 2003-410262 A1 20030410 (10)
PRAI US 2002-371511P 20020410 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 14 USPATFULL on STN

TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor- γ agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:312769 USPATFULL
TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
IN Needleman, Philip, Creve Coeur, MO, UNITED STATES
PA Pharmacia Corporation, St. Louis, MO (U.S. corporation)
PI US 2003220374 A1 20031127
AI US 2003-341174 A1 20030113 (10)
PRAI US 2002-348298P 20020114 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 14 USPATFULL on STN

TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

AB The present invention relates to methods and compositions for treating Alzheimer's disease and other diseases and conditions with an inflammatory component (e.g., central nervous system injury). In particular, the present invention provides agents that regulate the production of proinflammatory and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:25919 USPATFULL

TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

IN Landreth, Gary, Shaker Heights, OH, United States
Combs, Colin, University Heights, OH, United States
Silver, Jerry, Bay Village, OH, United States
Fitch, Michael T., S. Euclid, OH, United States

PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

PI US 6191154 B1 20010220

AI US 1998-200700 19981127 (9)

DT Utility

FS Granted

EXNAM Primary Examiner: Criares, Theodore J.

LREP Medlen & Carroll, LLP

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 38 Drawing Figure(s); 22 Drawing Page(s)

LN.CNT 3048

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

ABEN The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

ABFR L'invention concerne de nouveaux mimiques d'acyl-coenzyme A, des compositions contenant des composés cétone et des méthodes utilisées pour traiter et prévenir les maladies cardio-vasculaires, les dyslipidémies, les dysprotéinémies et les troubles du métabolisme du glucose. Ladite invention consiste à administrer une composition contenant un composé cétone. Les mimiques d'acyl-coenzyme A, les compositions, et les méthodes de l'invention sont également utiles pour traiter et prévenir la maladie d'Alzheimer, le syndrome X, les troubles liés au récepteur activé par le proliférateur de peroxisome, la septicémie, les troubles thrombotiques, l'obésité, la pancréatite, l'hypertension, la néphropathie, le cancer, l'inflammation, les

infections bacteriennes et l'impuissance. Dans certains modes de realisation, les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont utiles en polytherapie avec d'autres agents therapeutiques, tels que les agents hypocholesterolemians et hypoglycemians.

AN 2003087108 PCTFULL ED 20031031 EW 200343
 TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
 TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
 IN DASSEUX, Jean-Louis, 7898 Huron Oak Drive, Brighton, MI 48116, US;
 PA ONICIU, Carmen, Daniela, 125 Lake Village Drive, Ann Arbor, MI 48103, US
 AG ESPERION THERAPEUTICS, INC., 3261 South State Street, 695 KMS Place, Ann Arbor, MI 48101, US [US, US]
 AG INSOGNA, Anthony, M., Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US
 LAF English
 LA English
 DT Patent
 PI WO 2003087108 A2 20031023
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM
 TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC
 NL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2003-US11467 A 20030410
 PRAI US 2002-60/371,511 20020410
 L20 ANSWER 7 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
 TIFR MIMIQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
 ABEN The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dysphidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
 ABFR L'invention concerne de nouveaux mimiques d'acyl-coenzyme A, des compositions contenant des composes cetone et des methodes utilisees pour traiter et prevenir les maladies cardio-vasculaires, les dyslipidemies, les dysproteinemies et les troubles du metabolisme du glucose. Ladite invention consiste a administrer une composition contenant un compose cetone. Les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont egalement utiles pour traiter et prevenir la maladie d'Alzheimer, le syndrome X, les troubles lies au recepteur active par le proliferateur de peroxisome, la

septicemie, les troubles thrombotiques, l'obesite, la pancreatite, l'hypertension, la nephropathie, le cancer, l'inflammation, les infections bacteriennes et l'impuissance. Dans certains modes de realisation, les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont utiles en polytherapie avec d'autres agents therapeutiques, tels que les agents hypocholesterolemians et hypoglycemians.

AN 2003087040 PCTFULL ED 20031031 EW 200343
 TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
 TIFR MIMQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
 IN DASSEUX, Jean-Louis, 7898 Huron Oak Drive, Brighton, MI 48116, US;
 PA ONICIU, Carmen, Daniela, 125 Lake Village Drive, Ann Arbor, MI 48103, US
 PA ESPERION THERAPEUTICS, INC., 3621 South State Street, 695 KMS Place, Ann Arbor, MI 48101, US [US, US]
 AG INSOGNA, Anthony, M., Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US
 LAF English
 LA English
 DT Patent
 PI WO 2003087040 A2 20031023
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM
 TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC
 NL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2003-US11468 A 20030410
 PRAI US 2002-60/371,511 20020410

L20 ANSWER 8 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS
 TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS SELECTIFS DE LA CYCLOOXYGENASE 2.
 ABEN Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-γ agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.
 ABFR La presente invention concerne des procedes de traitement, prevention ou inhibition de la douleur, de l'inflammation, ou des troubles lies a l'inflammation et des procedes de traitement ou inhibition de maladies ou troubles cardio-vasculaires, ainsi que des procedes de traitement ou d'inhibition du cancer chez un sujet necessitant ce type de traitement, prevention ou inhibition. Ces procedes consistent a traiter le sujet a l'aide d'un agoniste γ du recepteur active du proliferateur du peroxysome, et d'un inhibiteur selectif de la cyclooxygenase-2 ou du promedicament de ce dernier. L'invention traite egalement de compositions, compositions pharmaceutiques et de kits pour mettre en oeuvre ces procedes.

AN 2003059271 PCTFULL ED 20030731 EW 200330
 TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME
 PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2
 SELECTIVE INHIBITORS
 TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU
 RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS
 SELECTIFS DE LA CYCLOOXYGENASE 2.
 IN NEEDLEMAN, Philip, 326 New Salem Drive, Creve Coeur, MO 63141, US [US,
 US]
 PA PHARMACIA CORPORATION, Mail Zone MC5S, 575 Maryville Centre Drive, .St.
 Louis, MO 63141, US [US, US], for all designates States except US;
 NEEDLEMAN, Philip, 326 New Salem Drive, Creve Coeur, MO 63141, US [US,
 US], for US only
 AG DUNLAP, Charles, E., Nelson Mullins Riley & Scarborough, Keenan
 Building, Third Floor, 1330 Lady Street, Columbia, SC 29201, US
 LAF English
 LA English
 DT Patent
 PI WO 2003059271 A2 20030724
 DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
 CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM
 TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC
 NL PT SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2003-US1099 A 20030114
 PRAI US 2002-60/348,298 20020114
 US 2003-10/341,174 20030113

 L20 ANSWER 9 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS
 TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP
 ABEN Compounds of the formula (I), wherein R<sb>1</sb>, R<sb>1</sb>-
 R<sb>7</sb>and alk have meaning as defined, pharmaceutical compositions
 thereof, and use
 thereof for the treatment and/or prevention of cardiovascular disorders
 responsive
 to ACE and NEP inhibition and/or ECE inhibition.
 ABFR L'invention concerne des composes de formule (I), dans laquelle
 R<sb>1</sb>, R<sb>1</sb>-R<sb>7</sb> et alk ont les designations
 specifiees,
 ainsi que des compositions pharmaceutiques de ces produits et
 l'utilisation
 de celles-ci pour le traitement et/ou la prevention de maladies
 cardiovasculaires
 sensibles a l'inhibition de ACE et NEP et/ou a l'inhibition
 de ECE.
 AN 2003027091 PCTFULL ED 20030410 EW 200314
 TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS
 TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP
 IN FINK, Cynthia, Anne, 1 Kensington Court, Lebanon, NJ 08833, US [US, US]
 PA NOVARTIS AG, Lichtstrasse 35, CH-4056 Basel, CH [CH, CH], for all
 designates States except AT US;
 NOVARTIS PHARMA GMBH, Brunner Strasse 59, A-1235 Vienna, AT [AT, AT],
 for AT only;
 FINK, Cynthia, Anne, 1 Kensington Court, Lebanon, NJ 08833, US [US, US],
 for US only
 AG GROS, Florent, Novartis AG, Corporate Intellectual Property, Patent &
 Trademark Department, CH-4002 Basel, CH
 LAF English

LA English
DT Patent
PI WO 2003027091 A1 20030403
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM
PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VC VN
YU ZA ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL
PT SE SK TR
AI WO 2002-EP10608 A 20020920
PRAI US 2001-60/323,825 20010921

L20 ANSWER 10 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
TIFR CONCEPTION ET SYNTHÈSE DE LIGANDS OPTIMISES POUR PPAR
ABEN This invention provides new chemical entities useful for treating a
variety of clinical disorders including those that are influenced by the
activity of peroxisome proliferator activated receptors (PPAR) including
PPARalpha, PPARdelta, and or PPARgamma. The structures of the compounds
and methods to design, make and use the compounds are provided.
Tautomers, stereoisomers and derivatives of the subject compounds, and
pharmaceutically acceptable salts and solvates thereof, and their uses
in the treatment of metabolic, inflammatory, autoimmune, proliferative
and degenerative diseases are also provided.
ABFR L'invention concerne des entites chimiques utiles dans le traitement de
troubles cliniques varies y compris de ceux qui sont influences par
l'activite de recepteurs actives du proliferateur de peroxysome (PPAR)
incluant PPARalpha, PPARdelta, et/ou PPARgamma. Elle concerne aussi les
structures de ces composes, et les procedes de conception, de
fabrication et d'utilisation de ces composes. Elle concerne enfin des
tautomeres, des stereoisomeres et des derives de ces composes, ainsi que
des sels et des solvates de ces composes, acceptables sur le plan
pharmaceutique, et leurs utilisations dans le traitement de maladies
metaboliques, inflammatoires, auto-immunes, proliferatives et
degeneratives.
AN 2002076177 PCTFULL ED 20021011 EW 200240
TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
TIFR CONCEPTION ET SYNTHÈSE DE LIGANDS OPTIMISES POUR PPAR
IN PERSHADSINGH, Harrihar, Ajodhya, 404 Windsor Park Drive, Bakersfield, CA
93311, US [US, US];
AVERY, Mitchell, Allen, 303 Woodland Hills Drive, Oxford, MS38655, US
[US, US]
PA BETHESDA PHARMACEUTICALS, INC., 404 Windsor Park Drive, Bakersfield, CA
93311, US [US, US], for all designates States except US;
PERSHADSINGH, Harrihar, Ajodhya, 404 Windsor Park Drive, Bakersfield, CA
93311, US [US, US], for US only;
AVERY, Mitchell, Allen, 303 Woodland Hills Drive, Oxford, MS38655, US
[US, US], for US only
AG JOHNSTON, Madeline, I., Morrison & Foerster LLP, 755 Page Mill Road,
Palo Alto, CA 94304-1018, US

LAF English
LA English
DT Patent
PI WO 2002076177 A2 20021003
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 AI WO 2002-US9287 A 20020325
 PRAI US 2001-60/278,097 20010323
 US 2001-60/283,774 20010413

L20 ANSWER 12 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
 TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
 ABEN The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatological, cardiovascular immunological, neurological, ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, and a PPAR γ ; agonist which cross-activates PPAR α ; or PPAR δ ; or both, or a PPAR γ ; partial agonist, or a PPAR γ ; /RXR agonist, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.
 ABFR L'invention concerne des procedes d'utilisation de ligands PPAR dans le traitement de maladies inflammatoires endocrines, dermatologiques, cardio-vasculaires, immunologiques, neurologiques, ophtalmiques, neoplasiques, pulmonaires, et de dysfonctionnements lies a l'age. L'invention concerne de plus des methodes de traitement de ces etats et maladies, qui comprennent l'etape consistant a administrer a un etre humain ou a un animal necessitant un tel traitement une quantite therapeutique de compositions pharmacologiques contenant un excipient pharmaceutiquement acceptable et un agoniste de PPAR γ ; qui active par reaction croisee PPAR α ; et/ou PPAR δ ; , ou un agoniste partiel de PPAR γ ; , ou un agoniste de PPAR γ ; /RXR permettant d'inverser, de ralentir, d'arreter ou de prevenir le processus inflammatoire ou degeneratif.
 AN 2002013812 PCTFULL ED 20020711 EW 200208
 TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
 TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
 IN PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
 PA PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
 LAF English
 LA English
 DT Patent
 PI WO 2002013812 A1 20020221
 DS W: AU CA MX NZ US
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 AI WO 2001-US25668 A 20010816
 PRAI US 2000-60/225,907 20000817
 US 2000-60/230,509 20000906

L20 ANSWER 13 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
 TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
 TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
 ABEN The present invention relates to methods and compositions for treating Alzheimer's disease and other diseases and conditions with an inflammatory component (e.g., central nervous system injury). In particular, the present invention provides agents that regulate the production of proinflammatory and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an inflammatory component.
 ABFR La presente invention concerne des methodes et des compositions de

traitement de la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante
inflammatoire (par exemple, des
lesions au systeme nerveux central). En particulier, la presente
invention concerne des agents
regulant la production de produits pro-inflammatoires et neurotoxiques
appliquees dans la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante
inflammatoire.

AN 2000032190 PCTFULL ED 20020515
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
IN LANDRETH, Gary;
COMBS, Colin;
SILVER, Jerry;
FITCH, Michael, T.
PA CASE WESTERN RESERVE UNIVERSITY
LA English
DT Patent
PI WO 2000032190 A1 20000608
DS W: AU CA IL JP KR AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE
AI WO 1999-US27987 A 19991124
PRAI US 1998-09/200,700 19981127

=> d his

(FILE 'HOME' ENTERED AT 12:59:47 ON 05 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006

L1 STRUCTURE UPLOADED
L2 7 S L1
L3 96 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006

L4 56 S L3
L5 1 S L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)
L6 38 S L3/THU
L7 17 S L6 AND PPAR
L8 3 S L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)
L9 5 S L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006

SEL L2
SEL L3

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006
SEA CIGLITAZONE AND ASTHMA

1 FILE AGRICOLA
1 FILE BIOENG
5 FILE BIOSIS
1 FILE BIOTECHABS
1 FILE BIOTECHDS
1 FILE CABA
12 FILE CAPLUS
5 FILE DDFU
5 FILE DRUGU

12 FILE EMBASE
 6 FILE ESBIODBASE
 4 FILE IFIPAT
 1 FILE LIFESCI
 7 FILE MEDLINE
 4 FILE PASCAL
 9 FILE SCISEARCH
 1 FILE TOXCENTER
 390 FILE USPATFULL
 62 FILE USPAT2
 5 FILE WPIDS
 1 FILE WPIFV
 5 FILE WPINDEX
 24 FILE EPFULL
 101 FILE IMSPATENTS
 1 FILE INPADOC
 1 FILE PATDPAFULL
 259 FILE PCTFULL

L10 QUE CIGLITAZONE AND ASTHMA

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006

L11 649 S CIGLITAZONE AND ASTHMA
 L12 203 S L11 AND PPAR

FILE 'EMBASE, CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006

L13 24 S CIGLITAZONE AND ASTHMA
 L14 18 S L13 AND PPAR
 L15 14 DUP REM L14 (4 DUPLICATES REMOVED)
 L16 0 S L14 NOT PY>2002

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006

L17 18 S L12 NOT PY>2002

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
 DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006
 SEA (E9-E111) AND ASTHMA

1 FILE CAPLUS
 1 FILE IFIPAT
 21 FILE USPATFULL
 2 FILE USPAT2
 1 FILE WPIDS
 1 FILE WPINDEX
 22 FILE PCTFULL

L18 QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"

FILE 'USPATFULL, PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006

L19 43 S (E9-E111) AND ASTHMA
 L20 14 S L19 NOT PY>2003